Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00827008 · ClinicalTrials.gov registry record · Phase 3
Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus
A Phase 3 study, sponsored by Merz Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 821
- Enrollment target
NCT00827008: Clinical Trial Phase 3 study, sponsored by Merz Pharmaceuticals.
NCT00827008 is a Phase 3 study that was terminated before completion, run by Merz Pharmaceuticals. The registered enrollment target is 821 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00827008, a Phase 3 study, was terminated before completion, sponsored by Merz Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 821 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the long-term safety and tolerability and efficacy of neramexane mesylate in the long-term treatment of subjective tinnitus after a completed double-blind randomized placebo controlled study
Interventions
- DRUG Neramexane mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 821 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Why NCT00827008 stopped before completion
NCT00827008 is an interventional study that assigns participants to a tested intervention. The registered 821 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Neramexane mesylate is the first listed.
NCT00827008 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00827008 about?
NCT00827008 is a clinical study titled "Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus". The purpose of this study is to investigate the long-term safety and tolerability and efficacy of neramexane mesylate in the long-term treatment of subjective tinnitus after a completed double-blind randomized placebo controlled study
What is the current status of trial NCT00827008?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 821 participants. The study started on 2009-01. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00827008?
The interventions under investigation include: Neramexane mesylate (DRUG).
Who is sponsoring clinical trial NCT00827008?
This trial is sponsored by Merz Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00827008's enrollment target sits among peer trials
821 404th of 2000 higher than 1,597 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05679349 · 822 participants · NA
Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking
- NCT06091254 · 822 participants · Phase 3
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- NCT07357389 · 822 participants · NA
Virtual Reality for ICU Delirium Prevention
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia